ReviewObesity pillars2026
Obesity and cellulitis: Associations with infection severity, recurrence, and healthcare utilization-A systematic review.
Review in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a growing global health concern associated with chronic inflammation, immune dysregulation, and impaired skin barrier function, all of which may increase susceptibility to cellulitis and influence clinical outcomes. This systematic literature review synthesized current evidence examining the relationship between obesity and cellulitis risk, infection severity, and healthcare utilization. Methods: This PRISMA 2020-guided systematic review and narrative synthesis searched PubMed/MEDLINE, Embase, CINAHL, and Web of Science for English-language primary studies published from January 2015 through December 2025. Eligible studies involved adults with cellulitis or erysipelas-or adult population cohorts reporting a separable cellulitis/erysipelas-specific outcome-evaluating body mass index (BMI) or obesity as an exposure or predictor. Target outcomes comprised cellulitis development or hospitalization, recurrence, treatment response or failure, severity, length of stay, readmission, cost, and mortality. Given the substantial heterogeneity across study designs and outcome definitions, findings were synthesized narratively. When sufficiently complete primary reports were available, risk of bias was evaluated using design-appropriate Joanna Briggs Institute (JBI) critical appraisal tools (Appendix 4). Results: Eighteen primary studies met the eligibility criteria. Across population cohorts and cellulitis-specific clinical studies, higher BMI or obesity was generally associated with greater cellulitis risk (e.g., ORs ranging from 1.11 to 4.7) and, in several studies, recurrence or increased healthcare utilization (such as prolonged length of stay). However, associations were not uniform: some studies reported null findings for treatment failure or readmission. The evidence base was predominantly observational and methodologically heterogeneous, so conclusions regarding downstream clinical outcomes are less certain than those regarding cellulitis risk and incidence. Conclusion: Obesity is an important risk marker of cellulitis susceptibility and adverse clinical outcomes. Future studies using standardized outcome measures and improved assessments of adiposity beyond BMI are needed to guide prevention strategies and optimize management of this growing population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.